Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Assets (2016 - 2026)

Cytosorbents filings provide 16 years of Assets readings, the most recent being $44.2 million for Q4 2025.

  • On a quarterly basis, Assets fell 6.73% to $44.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.2 million, a 6.73% decrease, with the full-year FY2025 number at $44.2 million, down 6.73% from a year prior.
  • Assets hit $44.2 million in Q4 2025 for Cytosorbents, down from $45.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $98.2 million in Q2 2021 to a low of $44.2 million in Q4 2025.
  • Median Assets over the past 5 years was $53.2 million (2023), compared with a mean of $62.3 million.
  • Biggest five-year swings in Assets: soared 99.34% in 2021 and later crashed 34.5% in 2022.
  • Cytosorbents' Assets stood at $89.5 million in 2021, then dropped by 29.37% to $63.2 million in 2022, then decreased by 16.25% to $53.0 million in 2023, then fell by 10.55% to $47.4 million in 2024, then decreased by 6.73% to $44.2 million in 2025.
  • The last three reported values for Assets were $44.2 million (Q4 2025), $45.8 million (Q3 2025), and $48.0 million (Q2 2025) per Business Quant data.